PositiveID uses assay partner GenArraytion's Zika test, the first commercially available multi-plexed PCR-based molecular test to identify dual lineages of the Zika virus
investors.positiveidcorp.com - May 25, 2016
DELRAY BEACH, Fla., May 25, 2016 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or "Company") (OTCQB:PSID), a life sciences company focused on detection and diagnostics, announced today that it has successfully detected the Zika virus on its Firefly Dx polymerase chain reaction ("PCR") breadboard prototype pathogen detection system ("prototype system"). . .
. . . PositiveID used assay partner GenArraytion, Inc.'s Aedes Aegypti MultiFLEX™ Bioassay test, which targets four genetic regions of the Zika virus, on PositiveID's Firefly Dx prototype system. The Zika virus test works with an existing GenArraytion MultiFLEX™ Bioassay panel that targets viruses that cause dengue fever, yellow fever and Chikungunya, which are also carried by the same mosquito and are known to cause febrile disease in humans. This test both identifies and discriminates between the Zika African and Brazilian lineages.
Recent Comments